launchedproduct line

Descovy

Q2 2026 sales rose 48% to $967 million.

The numbers

Product sales$967 millionQ2 2026 · +48% year over year · source ↗

Product sales$2,758 millionFY2025 · +31% year over year · source ↗

What it is

Descovy is an HIV treatment and, in its PrEP indication, a pill that reduces the risk of HIV infection. Its 2025 sales were $2.76 billion, up 31%, and growth has accelerated in 2026.

Why it matters to the stock. Descovy is now the second-largest HIV product by sales. Its growth is a read on demand for HIV prevention alongside Yeztugo.

News

No stories tagged to this project yet.